DK1755656T3 - Enzymer til farmaceutisk anvendelse - Google Patents

Enzymer til farmaceutisk anvendelse

Info

Publication number
DK1755656T3
DK1755656T3 DK05744343.4T DK05744343T DK1755656T3 DK 1755656 T3 DK1755656 T3 DK 1755656T3 DK 05744343 T DK05744343 T DK 05744343T DK 1755656 T3 DK1755656 T3 DK 1755656T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical use
enzymes
diabetes type
nocardiopsis
nrrl
Prior art date
Application number
DK05744343.4T
Other languages
English (en)
Inventor
Allan Svendsen
Svend Kaasgaard
Kim Borch
Morten Fischer
Dan Pettersson
Peter Colin Gregory
Original Assignee
Novozymes As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes As filed Critical Novozymes As
Application granted granted Critical
Publication of DK1755656T3 publication Critical patent/DK1755656T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK05744343.4T 2004-05-24 2005-05-24 Enzymer til farmaceutisk anvendelse DK1755656T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200400810 2004-05-24
DKPA200500101 2005-01-20
PCT/DK2005/000342 WO2005115445A1 (en) 2004-05-24 2005-05-24 Enzymes for pharmaceutical use

Publications (1)

Publication Number Publication Date
DK1755656T3 true DK1755656T3 (da) 2010-10-04

Family

ID=34968404

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05744343.4T DK1755656T3 (da) 2004-05-24 2005-05-24 Enzymer til farmaceutisk anvendelse

Country Status (12)

Country Link
US (2) US20110158976A1 (da)
EP (1) EP1755656B1 (da)
JP (1) JP2008500055A (da)
AT (1) ATE473010T1 (da)
AU (1) AU2005247061A1 (da)
BR (1) BRPI0510817A (da)
CA (1) CA2586222A1 (da)
DE (1) DE602005022187D1 (da)
DK (1) DK1755656T3 (da)
MX (1) MXPA06013239A (da)
RU (1) RU2389504C2 (da)
WO (1) WO2005115445A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US7892808B2 (en) 2003-10-10 2011-02-22 Norozymes A/S Protease variants
EP2258838A1 (en) 2004-06-21 2010-12-08 Novozymes A/S Nocardiopsis proteases
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
AU2008333313A1 (en) * 2007-12-04 2009-06-11 Novozymes A/S Protease variants for pharmaceutical use
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
CN102046782A (zh) * 2008-06-03 2011-05-04 诺维信公司 产生酪蛋白水解物的方法
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
WO2010002972A1 (en) 2008-07-01 2010-01-07 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CN105031628B (zh) 2009-01-06 2020-10-02 加尔纳根有限责任公司 治疗或预防大肠杆菌导致的经口感染的组合物和方法
AU2015252099B2 (en) * 2009-01-06 2017-08-10 Galenagen, Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
GB2480772B (en) 2009-01-06 2013-10-16 Curelon Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2011000924A1 (en) 2009-07-03 2011-01-06 Abbott Products Gmbh Spray-dried amylase, pharmaceutical preparations comprising the same and use
US8784884B2 (en) * 2009-09-17 2014-07-22 Stephen Perrett Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
EP2701733B1 (en) 2011-04-21 2019-04-03 Curemark, LLC Compounds for the treatment of neuropsychiatric disorders
BR112013032861A2 (pt) 2011-07-22 2017-01-24 Novozymes North America Inc métodos para aumentar a atividade da enzima celulolítica durante a hidrólise do material celulósico, para hidrolisar um material celulósico pré-tratado, para a produção de um produto da fermentação, e para a fermentação de um material celulósico pré-tratado
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
WO2014068083A1 (en) 2012-11-01 2014-05-08 Novozymes A/S Method for removal of dna
EP2910129A1 (de) * 2014-02-21 2015-08-26 Clariant Produkte (Deutschland) GmbH Zusammensetzung für die enzymatische Ölentschleimung
JP6607409B2 (ja) * 2017-03-31 2019-11-20 株式会社東洋新薬 経口用組成物
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
WO2023225459A2 (en) 2022-05-14 2023-11-23 Novozymes A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK564086A (da) 1986-11-25 1988-06-17 Novo Industri As Enzymatisk detergent-additiv
DK173590D0 (da) 1990-06-06 1990-07-19 Novo Nordisk As Rekombinante terapeutiske lipaser
US5614224A (en) * 1995-04-20 1997-03-25 Womack; Rick W. Nutritional supplement for diabetics
AU6221496A (en) * 1995-05-31 1996-12-18 Simon Lodewijk Scharpe Composition to improve digestibility and utilisation of nutr ients
FR2747045B1 (fr) * 1996-04-05 1998-06-26 Hooreman Michel Nouveau medicament optimisant la viscosite des mucus et ameliorant le fonctionnement de l'intestin
EP1162995B1 (de) * 1999-03-17 2003-06-04 Solvay Pharmaceuticals GmbH Enzyme zur behandlung von diabetes mellitus typ i
PL203212B1 (pl) 2000-02-08 2009-09-30 Dsm Ip Assets Bv Zastosowanie trwałej w kwasie proteazy w karmie zwierzęcej oraz w wytwarzaniu kompozycji do stosowania w karmie zwierzęcej, dodatek do karmy zwierzęcej, kompozycja karmy zwierzęcej i sposób obróbki białek roślinnych
AR032392A1 (es) 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
AU2003250830A1 (en) * 2002-06-12 2003-12-31 Bayer Healthcare Ag Regulation of human subtilase-like serine protease
CN103509776B (zh) 2003-06-19 2016-10-12 诺维信公司 蛋白酶
WO2004111222A1 (en) 2003-06-19 2004-12-23 Novozymes A/S Proteases
WO2004111219A1 (en) 2003-06-19 2004-12-23 Novozymes A/S Improved proteases and methods for producing them
US7892808B2 (en) 2003-10-10 2011-02-22 Norozymes A/S Protease variants

Also Published As

Publication number Publication date
ATE473010T1 (de) 2010-07-15
JP2008500055A (ja) 2008-01-10
EP1755656B1 (en) 2010-07-07
AU2005247061A1 (en) 2005-12-08
RU2006145899A (ru) 2008-06-27
RU2389504C2 (ru) 2010-05-20
CA2586222A1 (en) 2005-12-08
WO2005115445A1 (en) 2005-12-08
US20110158976A1 (en) 2011-06-30
MXPA06013239A (es) 2007-02-28
BRPI0510817A (pt) 2007-11-20
DE602005022187D1 (de) 2010-08-19
US20120207741A1 (en) 2012-08-16
EP1755656A1 (en) 2007-02-28

Similar Documents

Publication Publication Date Title
DK1755656T3 (da) Enzymer til farmaceutisk anvendelse
MX2007015474A (es) Proteasas para uso farmaceutico.
MX2007015471A (es) Amilasas para uso farmaceutico.
TW200738256A (en) Lipases for pharmaceutical use
HUP0500560A2 (hu) Mikróbás enzimek új keverékei
WO2005111203A3 (en) MUTANT α ΑMYLASES
MX2009006597A (es) Variantes de lipasa para uso farmaceutico.
DK1162995T3 (da) Enzymer til behandling af diabetes mellitus type I
MX2010005690A (es) Variantes de proteasa para uso farmaceutico.
NZ596269A (en) Protease screening methods and proteases identified thereby
JP2008521906A5 (da)
NO20065195L (no) Terapeutiske enzymformuleringer og anvendelser derav
WO2008021987A3 (en) Proteolytic enzyme formulations
MXPA02002901A (es) Enzimas de ruta de enfocado lisosomal.
WO2001097829A3 (en) Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
MY183252A (en) Kallirein 7 modulators
DE50106273D1 (de) Verwendung von aus ciliaten gewonnenen enzymen als verdauungsfördernde arzneimittel
EP1474509A4 (en) AGGRECANASE 1 AND 2 PEPTIDE SUBSTRATES AND METHOD
TH88730A (th) ไลเปสสำหรับการใช้ทางเภสัชกรรม
Skidgel Characterization of the metabolism of substance P and neurotensin by human angiotensin I converting enzyme and" enkephalinase".
Swietnicki A detailed study of enzymatic specificity of hepatitis A virus 3C proteinase.